WB-308

CAT: 0804-HY-116504Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-116504Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
WB-308 is a novel small molecule that was identified as an inhibitor of EGFR by an in vitro EGFR kinase activity system. WB-308 was able to reduce the proliferation and clonogenicity of NSCLC cells, causing G2/M phase arrest and apoptosis. In addition, WB-308 inhibited tumor growth in two in vivo animal models (lung orthotopic transplantation model and patient-derived clonal mouse model) . WB-308 impaired the phosphorylation of EGFR, AKT, and ERK1/2 proteins. Compared with Gefitinib, WB-308 had lower cytotoxicity. This study showed that WB-308 is a new EGFR-TKI that may be considered as an alternative to Gefitinib in the clinical treatment of NSCLC.
CAS Number
[1373764-87-4]
UNSPSC
12352005
Target
Akt; Apoptosis; EGFR; ERK
Type
Reference compound
Related Pathways
Apoptosis; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/wb-308.html
Smiles
FC1=CC2=C(C=C1)NC3=C2CCN(C3)C(CC4=CC=CC=C4)=O
Molecular Formula
C19H17FN2O
Molecular Weight
308.35
References & Citations
[1]Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products